Ram May-Ron of the FreeMind Group opens the 12th Annual Non-Dilutive Funding Summit with a few remarks on recent trends in life science R&D funding and the importance of federal grants as a strategic source of funds.
Dr. Ronald Hann of the Defense Threat Reduction Agency (DTRA) presents the keynote address on Preparing for the Unthinkable. View Slide Deck
Tyler Merkeley of the Biomedical Advanced Research and Development Authority (BARDA) CARB-X program talks about the novel non-dilutive partnership created to promote innovation and foster a robust antimicrobials pipeline. View Slide Deck
Paul McQuade of Greenberg Traurig, LLP shares some legal aspects of federal technology investment and their potential impact on intended markets. View Slide Deck
Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs. View Slide Deck
Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine. View Slide Deck
Mr. Henry Ahn of the National Science Foundation speaks on the NSF’s SBIR and STTR programs. View Slide Deck
Amber Dance Nature 540, 471–473 (15 December 2016) doi:10.1038/nj7633-471a Published online 14 December 2016 This article was originally published in the journal Nature Nervous about your grant application’s chance of success? Get help to make every word count. Read article online Jiri Lukas’ research centre was at a crossroads four years ago. Bankrolled by the Novo Nordisk Foundation, […]
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics. SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, […]